Clinical trials
Terminated Phase 1 Colorectal Neoplasms trials
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
127 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2000 | 1 |
| 2002 | 2 |
| 2003 | 2 |
| 2005 | 1 |
| 2006 | 3 |
| 2007 | 1 |
| 2008 | 2 |
| 2009 | 3 |
| 2010 | 1 |
| 2011 | 2 |
| 2013 | 3 |
| 2014 | 3 |
| 2015 | 5 |
| 2016 | 12 |
| 2017 | 9 |
| 2018 | 3 |
| 2019 | 12 |
| 2020 | 15 |
| 2021 | 8 |
| 2022 | 11 |
| 2023 | 14 |
| 2024 | 12 |
| 2025 | 1 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Terminated | 127 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Pfizer | 13 |
| Merck Sharp & Dohme LLC | 5 |
| Novartis Pharmaceuticals | 5 |
| AbbVie | 4 |
| Boehringer Ingelheim | 4 |
| Seagen Inc. | 4 |
| Ikena Oncology | 3 |
| Incyte Corporation | 3 |
| M.D. Anderson Cancer Center | 3 |
| Seagen, a wholly owned subsidiary of Pfizer | 3 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Colorectal Neoplasms | 127 |
| Carcinoma, Non-Small-Cell Lung | 49 |
| Melanoma | 34 |
| Neoplasms | 25 |
| Breast Neoplasms | 20 |
| Neoplasm Metastasis | 20 |
| Pancreatic Neoplasms | 20 |
| Squamous Cell Carcinoma of Head and Neck | 20 |
| Ovarian Neoplasms | 19 |
| Stomach Neoplasms | 18 |
Trials
Showing 1 to 25 of 127. Each trial links to its page on Pharma Observatory.
27 more trials match. See them on Pharma Observatory
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.